Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation

BACKGROUND: Diltiazem, a moderate cytochrome P450 3A4 isozyme/P‐glycoprotein inhibitor, may potentiate the bleeding risk of direct oral anticoagulants (DOACs) through pharmacokinetic interactions. We evaluated the association between concomitant use of diltiazem with DOACs and bleeding among patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yunwen, Chang, Alex R., Inker, Lesley A., McAdams‐DeMarco, Mara, Grams, Morgan E., Shin, Jung‐Im
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707838/
https://www.ncbi.nlm.nih.gov/pubmed/35861836
http://dx.doi.org/10.1161/JAHA.122.025723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9707838/
https://www.ncbi.nlm.nih.gov/pubmed/35861836
http://dx.doi.org/10.1161/JAHA.122.025723

Ejemplares similares